Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia

Boehringer IngelheimBoehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors. An "orphan receptor" is structurally related to a family of proteins that are known to act as functional cell-surface receptors but whose ligand has not yet been identified.

Arena will provide Boehringer Ingelheim exclusive rights to its internally discovered, novel compounds and intellectual property for an orphan CNS receptor. The companies will jointly conduct research to identify additional drug candidates that are suitable for continued research and development as therapeutic compounds for various disease indications. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.

According to the World Health Organization, mental illness - together with substance abuse disorders - remains the leading cause of disability worldwide. At least 450 million people(1) suffer from mental health problems. The global economic burden of mental illness is larger than for cancer, cardiovascular disease or diabetes and continues to grow - with significant health, social and economic consequences. As currently available treatment options leave many patients unsatisfactorily treated, more effective medicines for mental diseases are urgently needed.

"This agreement reflects our new corporate focus to enter into collaboration opportunities at various stages of development," said Harry F. Hixson, Jr., Arena's interim Chief Executive Officer. "Collaborations are an essential part of our drug discovery and development efforts, so we are pleased to be part of this shared goal to identify novel drugs targeting an orphan CNS receptor with Boehringer Ingelheim, who possesses demonstrated capabilities in research, development, manufacturing, and marketing of pharmaceutical products."

"Together with our research partners in neuroscience, we are targeting brain circuits underlying major untreated symptom domains in our CNS focus areas of Alzheimer's disease, schizophrenia, and depression. We are delighted to enter into this new collaboration with Arena, who have recognized expertise in orphan CNS GPCR drug discovery and development," said Corporate Senior Vice President Clive R. Wood, Head of Discovery Research of Boehringer Ingelheim. "We believe that this alliance with Arena will allow us to deliver innovative, new medicines for the treatment of patients with psychiatric diseases such as schizophrenia and contribute to our vision of helping the millions of people with mental illness, to live fuller, more independent lives, for longer."

The new partnership combines Arena's expertise in GPCR focused drug discovery and development with Boehringer Ingelheim's unique approach to CNS research and development and its proven capabilities in bringing novel medications of high therapeutic value to the market in areas of high unmet medical need.

The collaboration is part of Boehringer Ingelheim’s commitment to researching and developing new and more effective treatments for psychiatric diseases and their symptoms.

Under the terms of the agreement, Arena is eligible to receive payments up to $262 million in success milestones in case of full commercial success of multiple drug products, including an upfront payment and research funding. In addition, Arena is eligible to receive tiered royalties on future sales of products that arise from the collaboration. Further details of the agreement were not disclosed.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

About Arena Pharmaceuticals
Arena embraces the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's focus is discovering, developing and commercializing drugs to address unmet medical needs, and BELVIQ® (lorcaserin HCl) is Arena’s first internally discovered drug approved for marketing. Arena has US operations located in San Diego, California, and operations outside of the United States, including its commercial manufacturing facility, located in Zofingen, Switzerland.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

1. Saraceno, S. The WHO World Health Report 2001 on mental health. Epidemiologia e Psichiatria Sociale, June 2002; Vol. 11, Iss. 2:83-87.

Most Popular Now

Meditation, yoga and vegetarian diet linked to dec…

In a novel controlled clinical trial, participants in a six-day Ayurvedic-based well-being program that featured a vegetarian diet, meditation, yoga and massages experien...

Read more

Abbott to sell Abbott Medical Optics to Johnson …

Abbott (NYSE: ABT) announced today that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash. Abbott's vision bus...

Read more

Novartis convenes experts to discuss new technolog…

Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international univ...

Read more

Caffeine and its analogues revert memory deficits …

A study published in the journal Scientific Reports from Nature publishing group, describes the mechanism by which caffeine counteracts age-related cognitive deficits in ...

Read more

Amgen obtains global development and commercial ri…

Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG...

Read more

Vitamin C may boost effectiveness of acute myeloid…

A simple adjustment to patients' therapeutic regimen may improve the effectiveness of the standard epigenetic treatment for myeloid dysplastic syndrome (MDS) and acute my...

Read more

Roche ranked most sustainable healthcare company i…

For the eighth consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life...

Read more

10th European Medical Information and Communicatio…

29 - 30 November 2016, Berlin, Germany The 10th year of the Annual European Medical Information and Communications Conference is a unique meeting organised by medical in...

Read more

Saniona and Boehringer Ingelheim sign collaboratio…

Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, have ente...

Read more

Study shows how Chinese medicine kills cancer cell…

Researchers at the University of Adelaide have shown how a complex mix of plant compounds derived from ancient clinical practice in China - a Traditional Chinese Medicine...

Read more

Benralizumab phase III trials show positive result…

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care...

Read more

Antibody reduces harmful brain amyloid plaques in …

Although the causes of Alzheimer's disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]